Skip to main content

Table 1 Mean scores (standard deviation) for sociodemographic, clinical, cognitive and functional baseline characteristics across groups

From: Insights on the cognitive enhancement effect of desvenlafaxine in major depressive disorder

 

GROUPS

STATISTICS

 

MDD (n = 26)

HC (n = 40)

F or χ2

p-value

Age, years

48.8 (9.2)

45.93 (7.6)

1.85

0.178

Sex, n female (%)

17 (65.4)

22 (55)

0.7

0.402

Years of schooling, n

10 (3.4)

13.18 (3.4)

13.11

0.001

Estimated IQ, T-score

52 (14.6)

57.9 (8.3)

4.44

0.039

Age at illness onset, years

42.5 (12.1)

   

Depressive episodes, n

1.8 (1.1)

   

Duration of the current episode, n

40.6 (26.82)

   

Baseline medication, n (%)*

    

 Sertraline

9 (34.6)

   

 Fluoxetine

3 (11.5)

   

 Paroxetine

7 (26.9)

   

 Citalopram

5 (19.2)

   

 Escitalopram

2 (7.7)

   

HDRS-17, total score

23.1 (3.3)

2.5 (2.8)

735.05

< 0.001

CGI Severity, total score

4.1 (0.4)

   

RDQ, total score

56.5 (10.9)

   

HARS, total score

25.1 (5.5)

3.1 (3.5)

369.17

< 0.001

Attention/Working Memory, T-score

42.1 (6.6)

49.9 (10.6)

11.27

0.001

Verbal Memory, T-score

40.9 (8.7)

48.1 (9.4)

9.91

0.003

Processing Speed, T-score

48.2 (8.4)

53.9 (7.1)

8.52

0.005

Executive Function, T-score

43.4 (7 − 4)

49.7 (5.9)

14.30

< 0.001

PDQ-D-5, total score

12 (3.3)

4.3 (2.4)

114.53

< 0.001

FAST, total score

45.6 (12)

9.2 (7.9)

218.55

< 0.001

SDS, total score

23.6 (4.6)

   
  1. MDD: Major Depressive Disorder, HC: Healthy Controls, IQ: Intelligence Quotient, HDRS-17: 17-item Hamilton Depression Rating Scale, CGI: Clinical Global Impression, RDQ: Remission from Depression Questionnaire, PDQ-D-5: Perceived Deficit Questionnaire-Depression 5-item, FAST: Functioning Assessment Short Test, SDS: Sheehan Disability Scale. *Baseline medication prior to desvenlafaxine.